Cosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque.
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa • Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade • Committee for Medicinal Products for Human Use (CHMP) opinion based.